share_log

默克宣布终止两种实验性抗癌药物的开发

Merck announced the termination of the development of two experimental anticancer drugs.

Gelonghui Finance ·  Dec 17 13:31

On December 17, Gelonghui reported that Merck announced on Monday that it has halted the development of the experimental cancer drugs vibostolimab and favezelimab after multiple trials failed when combined with the best-selling drug Keytruda to treat various cancers. Marjorie Green, head of Global Clinical Development Oncology at Merck Research, stated: "After careful analysis of the data, we have decided to stop the development of these candidate drugs to prioritize other ongoing projects."

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment